The daily dosage of Ibrutinib should be adjusted according to the indications, age, and liver function status. It is usually taken orally once a day in a single dose, and the specific number of tablets depends on the drug specifications. The specific treatment course varies depending on the indications, and the medication plan should be strictly adjusted according to the doctor's advice.

1 Standard Dose Protocol

(1) Adult chronic lymphocytic leukemia/small lymphocytic lymphoma: 420mg once daily (if 140mg per tablet, 3 tablets are required).

(2) Adult Fahrenheit macroglobulinemia: 420mg once daily, used alone or in combination with rituximab.

(3) Chronic graft-versus-host disease: Patients over 12 years old take 420mg per day, and children aged 1-12 take 240mg/m ² per day (maximum 420mg).

Principle of dose adjustment

(1) Liver function impairment: Mild reduced to 140mg/day (1 tablet), moderate reduced to 70mg/day (half a tablet), and severe avoided.

(2) Children with GVHD accompanied by elevated bilirubin: reduced to 140mg/day for those over 12 years old, and reduced to 80mg/m ²/day for those aged 1-12 years old.

3 Precautions for administration

(1) The whole tablet cannot be divided and is recommended to be taken at a fixed time. It should be given priority when combined with rituximab.

(2) If a grade ≥ 3 adverse reaction occurs, medication should be suspended and adjusted according to the stepwise reduction plan after recovery.

4 Special Instructions

(1) Renal dysfunction and elderly patients do not require dose adjustment, but close monitoring of adverse reactions is necessary.

(2) When taken with a high-fat meal, absorption increases by 2 times. It is recommended to maintain consistency in the medication method.

5 Basic principles of medication cycle

(1) Continuous treatment mode: It is recommended to administer a fixed daily dose without a fixed course of treatment, and it should be continued until the disease worsens or the toxicity is intolerable.

(2) Dynamic evaluation mechanism: During the treatment period, it is necessary to regularly monitor the efficacy indicators and adverse reactions, and decide whether to continue or terminate the treatment based on the evaluation results.

Differences in treatment courses for 6 different indications

(1) Chronic lymphocytic leukemia/small lymphocytic lymphoma: requires long-term maintenance treatment, and clinical studies have shown that continuous medication can prolong progression free survival.

(2) Fahrenheit macroglobulinemia: The same continuous administration strategy is used until the disease progresses or serious adverse reactions occur.

(3) Chronic graft-versus-host disease: Medication should be discontinued when the disease no longer requires treatment, but most patients require long-term maintenance.